Covidien has received European Economic Area (EEA) CE Mark approval for its Puritan Bennett 980 ventilator, designed to deliver advanced breath technology with enhanced patient comfort and clinician ease-of-use.
The Puritan Bennett 980 ventilator helps clinicians set the ventilator to adapt to their patients’ unique needs and provide the appropriate level of support throughout the breath.
It is designed for patients ranging from neonatal to adult.
The next-generation acute ventilation platform offers a range of software capabilities, including proportional assist ventilation plus (PAV+) technology, licensed from University of Manitoba in Canada that provides smarter pumping to optimally synchronise with every patient and leak sync software.
PAV+ technology has been shown to help reduce asynchrony, which studies have shown may ease days on mechanical ventilation.
With its range of software capabilities, the new ventilator system helps clinicians get patients off mechanical ventilation as early as possible.
Covidien Europe president Cristiano Franzi said: "Building on Covidien’s strong legacy of innovation, the Puritan Bennett 980 ventilator will provide clinicians with a simple, safe and smart way to care for patients."
On February 26, the company obtained US Food and Drug Administration (FDA) 510(k) clearance for the Puritan Bennett 980 ventilator.
The system was also approved for commercial distribution in Japan and Canada and will be available for sale in those countries, as well as the EEA in the coming months.
According to GlobalData estimates, the Europe ventilators market was valued at $169m in 2012 and is expected to grow at a CAGR of 3.4% to reach $214m by 2019.
Image: Puritan Bennett 980 ventilator gets CE Mark clearance. Photo: courtesy of Covidien/Business Wire.